Today’s AI Top Pick: TASK

7/30/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · TASK85%298 resolved forecasts · 45d window · verify →

Today's pick · Low Float Bullish Consensus Deep RotationTASKBUY NOW8.1 / 107/30/2026

TASK is the cleanest fundamental-plus-tape setup in the pool. It carries a bullish_prob of 1.0 and near_term_bullish of 0.8, with multi-timeframe forecast agreement pointing up on 4h (+37.5/+65.6/+66.7%), 1d (+15.7/+27.3/+12.6%) and 1wk (mid +11.7%, long +21.6%). The only wart is a mildly negative 1h forecast (-6.4/-17.5/-14.6%), which suggests a short-term breather rather than trend break. Crucially, the fundamentals are the strongest in the entire screen: PE 5.72, fwdPe 4.22, PEG 2.19, ROE 26.52%, profitMargin 8.7%, salesYoY +15.95%, debtEq manageable at 1.99, and analyst targetUpsidePct of +35.6%. Fundamental score 5.25 is the second-highest and it is a real cash-flow business, not a $5M shell. Yes, TASK is elevated in its 21-bar range (1d at 100%, 4h at 97.5%, RSI 68), which normally screams 'don't chase.' But look at the 1wk frame: position 67.3% and drawdown -11.9% from the weekly high — meaning the daily/4h breakout is happening from within a longer-term base, not a blow-off top. The name is still down -41.6% over the past year and -15.5% YTD, so this is early-recovery structure on a fundamentally cheap name. News confirms rather than undercuts: Wedbush (Jul 24) called top-client-exit risk unlikely, Zacks flagged the 5.1% surge on Jul 28, and there are no dilution/legal/short-seller landmines in the recent tape. Compare to peers like IPWR (just filed $75M shelf), CALC (filed 56M-share resale prospectus), PRSO ($25M Roth equity line), NXTC (all-stock merger + $320M PIPE), QCLS (license terminated) — all of which have material overhangs that undercut their forecasts. Why today vs. waiting: the 1h fade is likely to give a modest pullback into $6.20–6.35, and that IS the entry. Waiting for a deep pullback risks missing a 4h/1d structure that already shows +27–66% forecast magnitude, and this is the only screen candidate that combines profitable business, cheap multiple, strong analyst support (recom 2.86 is the weakest link but targetUpsidePct 35.6% is real), and confirming multi-TF signals.

Entry zone

$6.20–$6.55 (buy half at market ~$6.54, add on any dip toward $6.20 which is the 1h dd_from_high area)

Stop loss

$5.75 (below the 4h/1d breakout base; ~12% risk)

First target

$7.50 (near-term, roughly aligned with 4h fc_short +37% off pullback lows and 1d fc_short zone)

Longer target

$8.85 (matches analyst targetUpsidePct +35.6% and 4h fc_long +66% off a $5.30 base)

Risks

Short float 11.31% and RSI 68 — chasing risk if you buy above $6.70 without a pullback
1h forecast is negative (-6.4% short, -17.5% mid) suggesting near-term digestion before the next leg
Analyst recom is 2.86 (weakest among screen leaders) — Street is not uniformly bullish despite the upside target
Debt/Equity 1.99 is elevated; any macro risk-off (SEC-noted South Korea market weakness in broader news) could compress the multiple
1d position at 100% of 21-bar range — a failed breakout candle would trap late buyers back into the $5.80s

Honorable mentions

LTRNBullish_prob 1, near_term 0.8, all four TFs pointing up (1d fc_mid +37.8%, 1wk fc_long +56.4%), position 0% in 1h/4h/1d range (not chasing), and two clean positive catalysts: EMA clearance for LP-184 Phase 1b/2 (Jul 28) and USPTO Notice of Allowance (Jul 23). Fundamentals are weak (biotech, negative margins) so it's sized smaller.

IDNBest combination of screen fundamentals (PE 34, ROE 11.4%, profit margin 9.6%, targetUpsidePct 102%) with low position-in-range (1h 23%, 4h 11%, 1d 13.5%). 1h/4h/1d forecasts strongly positive (+23 to +155%). Weekly forecast is slightly negative which is the only reason it's not #1 — better as a swing after a base builds.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	TASK	BUY NOW	8.1	Cheap profitable name (fwdPe 4.22, ROE 26.5%) with 4h/1d/1wk forecasts aligned up and confirming news flow.
2	LTRN	BUY NOW	7.2	Clean multi-TF bullish stack with EMA clearance and patent catalysts; position at 0% of range = no chase.
3	IDN	BUY PULLBACK	6.8	Best fundamentals of the small-caps, 1h/4h/1d forecasts +23 to +155%, but weekly still bearish.
4	GRCE	BUY NOW	6.4	FDA Type A minutes confirm no clinical deficiencies (Jul 28); 4h/1d/1wk forecasts +10 to +71%, position 0% in range.
5	GLMD	BUY PULLBACK	6.0	Multiple positive Aramchol pipeline catalysts; near_term 0.8 with 1d fc_long +115% but micro-cap risk.
6	BCDA	BUY PULLBACK	5.7	Weekly forecast +183/+194/+186%, deep 4h drawdown -38.9% = base; no headline landmines but micro-cap illiquid.
7	QNTM	WAIT	5.5	1d/4h forecasts +100%+ but ROE -984% and no fundamentals — pure speculative bounce.
8	DRMA	WAIT	5.3	Weekly forecast +3102–8785% is a data outlier; treat with extreme skepticism at $4.75M cap.
9	NXL	BUY PULLBACK	5.3	Multi-TF positive except weekly; near_term 0.6, salesYoY +110%, but micro-cap and weak margins.
10	COCP	BUY PULLBACK	5.2	Near_term 1, all TFs positive on 1h/4h/1d, but PS 52.17 and profitMargin -3924% — pure catalyst-driven trade.
11	PRSO	WAIT	5.0	Near_term 1 and 1h/4h/1d forecasts +35–72%, but Roth $25M equity line (Jul 2) is a dilution overhang.
12	CNCK	BUY PULLBACK	4.9	1wk fc_mid +388% and 1d fc_mid +85% but 1h forecast -10% and fwdPe 1414 makes this a pure narrative trade.
13	RGNT	BUY PULLBACK	4.8	Japan Patent + European regulatory approval catalysts, but only 2 TFs available and 1d down -61.5%.
14	XTLB	WAIT	4.6	Positive YTD +27.6% is the only screen name with positive perf, but forecasts split and 1h/4h at top of range.
15	CALC	AVOID	4.5	Filed 56M share resale prospectus (Jul 24) undercuts the +220% mid-forecast — pure dilution risk.
16	YCBD	BUY PULLBACK	4.4	Near_term 1 with 1h fc_long +85%, but only 3 TFs and small partnership news isn't a needle-mover.
17	INTZ	WAIT	4.2	Near_term 1 and all TFs positive but recent tape shows two down days (Jul 21, Jul 29) — momentum stalled.
18	AKTX	WAIT	4.0	1d fc_mid +122% but 1h -26/-43/-52% and 1wk -40.9% flat across horizons — mixed structure.
19	NXTC	AVOID	3.8	All-stock merger with Avere + $320M PIPE (Jul 14) fundamentally reshapes the entity — thesis is broken.
20	MORN	AVOID	3.7	Chasing top (position 100%, RSI 71.9) and 1h/4h forecasts sharply negative; earnings beat already priced in.
21	IPWR	AVOID	3.5	Filed $75M shelf prospectus (Jul 10) — direct dilution overhang neutralizes the +100% 1h forecast.
22	HXHX	WAIT	3.4	Reasonable fundamentals (PE 11, ROE 17%) but bullish_prob null and small $31M financing raises dilution concern.
23	CRE	WAIT	3.2	PE 6.45 and 1d fc_long +85% but perfYear -95.9% signals broken structure; only 3 TFs available.
24	LUCY	AVOID	3.1	Warrant exercise for $3M (Jul 8) confirms ongoing dilution; recom 3 (Hold) and only 3 TFs.
25	GXAI	AVOID	3.0	Stock slid on Jul 28 despite positive strategy update; all TFs positive on forecast but 1wk down -41%.
26	WW	AVOID	2.9	Only 1d TF available; sector mismatch flag (listed Consumer Cyclical vs Healthcare); insufficient signal.
27	SSM	AVOID	2.8	Only 2 TFs, 1wk fc_long -92.9% is a killer, and profitMargin -5377% is untradeable.
28	USBC	AVOID	2.5	1d forecast -30% contradicts 1wk +1962% — data noise, not a signal; targetUpsidePct 12,803% is unusable.
29	QCLS	AVOID	2.0	Terminated Lightsolver license (Jul 2) and 1d/1wk forecasts -96/-100% — broken.
30	HSCS	AVOID	1.8	Reverse merger with Fortitude Mining pivots the entity away from HeartSciences — thesis void.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord